ArticleDiscover oncology2025
Investigation of biomarkers and associated molecular mechanism shared between colorectal cancer and lung adenocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Key genes and pathway differences between serrated polyps and conventional adenomas: insights from multi-omics.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe relationship between colorectal cancer (CRC) and lung adenocarcinoma (LUAD) has been acknowledged in recent years, yet the biomarkers and mechanisms underlying their interaction remain unclear. This study aimed to explore the genetic characteristics and molecular mechanisms shared by CRC and LUAD.
methodsTo identify common differentially expressed genes (co-DEGs) between tumor and normal samples, we analyzed gene expression datasets for CRC and LUAD from the GEO and TCGA databases. Then, co-DEGs were further analyzed for enrichment. The survival analysis and protein-protein interaction (PPI) analysis were used to explored biomarkers for two diseases. Based on the identified biomarkers, the functional similarity, immune cell infiltration, and Gene Set Enrichment Analyses (GSEA) were performed. Moreover, the drug-gene interaction was predicted based on biomarkers. Finally, the qRT-PCR, Western blotting, and enzyme-linked immunosorbent assay (ELISA) to validate the expression of these biomarkers in CRC and LUAD based on cell lines and mice model.
resultsWe explored totally 3470 co-DEGs of tumor vs. normal based on CRC and LUAD dataset. K-M survival and PPI network analysis revealed five hub prognostic genes, including HSPA6, NOTCH3, PKP2, SMAD9, and GPD1L, as biomarkers for two diseases, with enrichment analysis showing that biomarkers like HSPA6 and SMAD9 were primarily associated with protein binding functions. Functional similarity analysis revealed that the five biomarkers exhibited a high degree of similarity in their biological roles, with NOTCH3 showing the highest similarity, further supported by immune infiltration analysis indicating a significant and strong positive correlation between NOTCH3 and Natural Killer cells. Finally, the expression investigation of five biomarkers based on cell lines and mice model validated the results of bioinformatics analysis.
conclusionsHSPA6, NOTCH3, PKP2, SMAD9, and GPD1L were five novel biomarkers for CRC and LUAD clinical diagnosis or treatment. HSPA6 and SMAD9 might take part in the progression of CRC and LUAD via protein binding function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.